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Nowadays nano- and micro-crystals of CaCO3 are extremely attrac-
tive as vectors for direct loading and controlled release of biologically
active molecules as well as decomposable matrices for hard templating
of polymer-based particles [1–6].
Vaterite polymorph of CaCO3 is of special interest [1] because it can
be easily synthetized in laboratory from inexpensive precursor salts
(e.g. CaCl2 and Na2CO3) yielding crystals of adjustable dimensions rang-
ing from hundreds of nanometres up to tens of micrometres. In addi-
tions to biocompatibility, the vaterite crystals are mesoporous, i.e.
have pore sizes in the range of tens of nanometres that allows effectively
hosting and protecting both small compounds (e.g. antibiotics, antican-
cer and other drugs [7], nanoparticles [8]) and rather large
biomacromolecules (proteins [9–11], hormones [12], enzymes [13],
RNA [14]). Besides the dimensions, porosity [15] and the shape of the
crystals [16] can be modulated in a broad range, accordingly to the
area of applications of the crystals.
The crystals can serve as sacriﬁcial templates to assemble multilayer
capsules [17], macrostructures such as scaffolds [18–21] as well as po-
rous particles made of biologically relevant functional molecules such
as polyethylene glycol and poly-N-isopropylacrylamide [22,23]. The
crystals have been employed as tailor-made matrices for diagnostics,
e.g. using Raman spectroscopy [24,25], and can be functionalised pro-
viding external control over drug release [26]. Vaterite CaCO3 crystals
can be multifunctional in regards with their role as templates, e.g.
they can serve as porogens and a source of calcium to assemble porous
alginate gels with biomolecules loaded into the pores [27,28].
Both low- and high-molecular-weight bioactives have been success-
fully encapsulated into the vaterite crystals, yet negatively charged pro-
teins can be loaded into crystals in signiﬁcantly high amounts [29],
whereas positively charged bioactives can scarcely be loaded in sub-
stantial amounts and are quickly released from the crystals upon wash-
ing. This has been demonstrated for protamine and aprotinin (APR)
[29], lysozyme [30] and doxorubicin (DOX) [31].
A number of synthetic polymers added during the growth of CaCO3
crystals can affectmorphology and thermodynamic state of the crystals:
poly(sodium 4-styrene-sulfonate), poly(allylamine hydrochloride),
poly (acrylic acid), poly (vinyl alcohol), polyacrylamide, poly(N-isopro-
pyl acrylamide), poly(N-vinyl pyrrolidone), poly(ethylene oxide,
carboxymethyl cellulose [32–34]. Biopolymers such as pectin, carra-
geenan, alginate, chitosan, xanthan, hyaluronic acid, heparin have
been reported to affect the crystal properties [32,33]. In spite of signiﬁ-
cant inﬂuence of the polymers on the crystal properties and structure,
the formulation of polymer-containing hybrid crystals may open new
ways for the encapsulation of themolecules of interest via their binding
to the polymer matrix. Some examples for such two-component
vaterite crystals have been recently reported. For instance,
carrageenan-CaCO3 crystals can host DOX and release the drug in a
sustained manner [31]. Recently, DOX-loaded hyaluronate calcium car-
bonate hybrid nanoparticles have been successfully designed for the in-
hibition of the tumour [35]. Similarly to small drugs like DOX, protein-
based drugs have been encapsulated into polymer-containing vaterite
crystals: heparin-CaCO3 hybrids can host large amount of lysozyme
and keep it during layer-by-layer coating of the crystal [30], thematrices
of silane-coupling polymers facilitate the retention of cisplatin (one of
the most successful chemotherapeutics) [36].
In recent years, a surge of interest to the loading of the vaterite crys-
tals withmucoadhesive biopolymers such asmucin has emerged to em-
ploy the crystals for drug delivery inmucosa [7,37].Mucins are themain
components of mucousmembranes in the gastrointestinal tract, as well
as nasal and oral mucousmembranes [38]. These large extracellular gly-
coproteins havemolecular weights ranging from 0.5 to 20MDa. Mucins
are classiﬁed as membrane-bound and secreted mucins and both types
share many common features [39]. They consist of 80% carbohydrates
which are mainly N-acetylgalactosamine, N-acetylglucosamine, fucose,galactose, and sialic acid (N-acetylneuraminic acid); remaining 20%
constitute the protein core. The oligosaccharide chains built up of
5–15 simple sugars are attached to the hydroxyl side chains of serine
and threonines of so called central glycosylated region of the protein
core which is comprised of multiple tandem repeats rich in serine, thre-
onine, and proline (STP repeats). At the amino and carboxy terminals, as
well as between STP repeats, there are regions of the second type that is
called cysteine-rich domain as the content of cysteine in these regions is
N10%. Disulﬁde bonds formed between cysteine-rich domains of
neighbouringmucinmolecules lead to subsequent dimerization andpo-
lymerization of glycoprotein. Due to this structure a number of various
interactions are present inmucins including electrostatics, hydrophobic
interactions, and hydrogen bonding; these interactions largely deﬁne
the properties ofmucins (Fig. 1). In our previous paperwe have demon-
strated loading of mucin into the vaterite crystals via physisorption [40]
and co-synthesis at low concentrations below 1 mg mL−1 [37]. These
studies demonstrated a high promise for the use of mucin-containing
formulations for drug delivery via mucosa; now we address the chal-
lenge of the design of hybrid drug delivery systems for effective deliver
of small cationic drugs in a sustained manner.
In present work, we develop novel mucin-containing vaterite crys-
tals for effective loading and controlled release of small cationic drugs.
We have utilized DOX - a drug that is widely used in therapy of numer-
ous cancers. DOX formulations are widely used via oral and intravenous
administrations into cervical [41] and lung carcinoma [42,43], primary
and metastatic melanoma [44], osteosarcoma [45] and hepatoma [46],
providing long-term release performance [14,47–49], however limited
intestinal absorption of DOX via mucosal surfaces is not yet fully
circumvented [48]. In addition to DOX, loading and release of two
protein-based therapeutics (protease inhibitor aprotinin and hormone
insulin), are also investigated. We discuss on fundamentals of the
CaCO3 biomineralization and potential of hybrid crystals for controlled
drug delivery.
2. Experimental section
2.1. Materials
Anhydrous calcium chloride, ≥93.0% (C1016), anhydrous sodium
carbonate Na2CO3, ≥99.0% (S7795), commercial mucin from porcine
stomach, Type III, (m1778), aprotinin, N-benzoyl-L-arginine ethyl
ester, N-acetylneuraminic acid from E. coli (Sigma-Aldrich, USA); tryp-
sin from bovine pancreas (Fluka, Germany); doxorubicin hydrochloride
substance (Dian Jiang Chong, China). Human recombinant insulin zinc
salt was kindly provided by the Experimental Biotechnology Plant of
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian
Academy of Sciences. All chemicals for buffer solutions were laboratory
grade and purchased from Sigma–Aldrich, USA. Before use, mucin solu-
tions were sonicated for 30 min using the ultrasonic bath (Elmasonic
S15H, Germany).
2.2. Analytical determination of mucin and drugs
The concentration of DOX in the solutions was determined spectro-
photometrically at 480nm(ε=12,500M−1 cm−1) [50]. The concentra-
tion of active aprotinin in the solutions was determined by inhibition of
trypsin using BAEE substrate as described [51,52]. In the study of ad-
sorption isotherms, the concentration of the mucin in solution was de-
termined spectrophotometrically at the wavelengths of 260 nm. In all
other experiments concentration of mucin and insulin in solution
were determined by analytical size exclusion chromatography [37] in
the Biofox 17 SEC 8 × 300 mm column (Bio-Works, Sweden) using
the Smartline chromatographic system (Knauer, Germany) in a solution
of 0.15МNaCl. Preliminarily, the columnwas calibrated using solutions
of puriﬁed mucin and insulin with different concentrations
(0.01–0.1 mg mL−1) and proteins with different molecular weights. A
Fig. 1. Schematic structure of mucin and its mucoadhesive elements highlighting potential sites for mucin-DOX interaction.
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tography analysis at the elution rate of 0.5mLmin−1. Absorbance of the
eluted solutions wasmeasured using the UV detector at wavelengths of
214 nm and 260 nm.
The content of sialic acids in mucin, determined by Hess's method
using the calibration curve for N-acetylneuraminic acid and was found
to be 2.30 ± 0.10% [37].
2.3. Preparation and characterization of the CaCO3-mucin-drug hybrids
3mL of the solution (water or 0.05M TRIS buffer, pH 7.1) containing
0.167–10 mg mL−1 mucin and/or 1.67 mg mL−1 protein (APR/INS) or
0.167 mg mL−1 DOX were added to 1 mL of the solution 1 M CaCl2.
The solution was stirred for 5 min (100 rpm). 1 mL of the solution of
1 M Na2CO3 was added and further stirred for an additional 45 s. Then
the suspensionwas incubated for 15min. The precipitate was separated
by centrifugation (2min, 1000 g) andwashed twicewith 5mL of water.
If necessary, the particles were dried. The mass of the precipitate was
determined, and the mass of CaCO3 was calculated assuming the com-
plete process of crystallization of the insoluble crystals. The concentra-
tions of mucin and drug were determined in the supernatant and
washing solutions.
The amount of adsorbed mucin saturation conditions (equilibrium)
was calculated using the following equation:
qe ¼
C0−Ceð Þ  V
m
ð1Þwhere qe is the adsorption capacity (mg g−1), С0 and Ce are the initial
and equilibrium concentrations (mg mL−1); V is the volume (mL) of
the solution; andm is the mass (mg) of CaCO3.
Efﬁciency of mucin or drug incorporation was calculated using the
equation:
η ¼ C0−Ce
C0
ð2Þ
The isotherm for mucin loading via co-synthesis (initial mucin con-
centration 0.1–6 mg mL−1) has been constructed based on Langmuir
adsorption model according to the Langmuir equation below:
qe ¼
qmaxKaCe
1þ KaCe ð3Þ
where qe – equilibrium adsorption capacity (mg g−1); Cе – concentra-
tion of mucin in the solution at equilibrium (mg mL−1); qmax – maxi-
mum adsorption capacity (mg g−1); Ka – adsorption equilibrium
constant (mL mg−1).
The free Gibbs energy (ΔG) has been calculated as−RT ln Ka, where
R is the universal gas constant, 8.31 (J K−1 mol−1); T is the temperature
(K); Ka is the constant of adsorption equilibrium in units of L mol−1.
2.4. Study of drug release
The centrifuged precipitate of the CaCO3 crystals was combinedwith
5 mL 0.05 M TRIS buffer, pH 7.4. The suspension was continuously
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trifuged (2min, 10,000 g), and analyzed. Themucin or drug release was
estimated by the ratio of the concentrations of the supernatant and
suspension.
2.5. Microscopy analysis
CaCO3 crystals were visualized using an optical microscope Carl
Zeiss, JENA (Germany) to get transmission light images. Scanning elec-
tronmicroscopy (SEM) images were recorded using a Gemini LEO 1550
electron microscope at an accelerating voltage of 3 kV. Samples were
prepared by dropping the crystal suspension on a glass slide, dried
within 1 h at 90 °C and followed by conductive coating with gold palla-
dium (5 nm).
2.6. ζ-potential measurement
The ζ-potential of CaCO3 crystals and mucin was measured using
Zetasizer (Nano ZS, Malvern, UK) and estimated using Smoluchowski
eq.
2.7. ATR-FTIR spectroscopy
ATR-FTIR spectra were recorded using a Bruker Tensor 27 spectrom-
eter equipped with a liquid nitrogen cooled MCT (mercury cadmium
telluride) detector. Samples were placed in a thermostatic cell BioATR-
II with a ZnSe ATR element (Bruker). The FTIR spectrometer was purged
with a constant ﬂow of dry air. FTIR spectra were acquired from 900 to
3000 cm−1 with 1 cm−1 spectral resolution. For each spectrum, 100
scans were accumulated at 20 kHz scanning speed and averaged. All
samples were prepared in aqueous buffer solution using deionized
water at 22 °C. Spectral data were processed using the Bruker software
Opus 7.5 as described elsewhere [53–55], which includes linear blank
subtraction, straight-line baseline correction and atmosphere compen-
sation. If necessary, seven- or nine-point Savitsky–Golay smoothing
was used to remove white noise. The peaks were identiﬁed by standard
Bruker picking-peak procedure.
Solid-phase ATR-FTIR spectroscopy of lyophilized precipitates was
conducted with Vertex 70 V Bruker machine (Germany) equipped
with PLATINUM ATR diamond cell. Spectra were registered with
4 cm−1 resolution from 4000 cm−1 to 350 cm−1, 24 scans for each spec-
trum. Spectra were analyzed with Bruker Opus 7.0 software.
2.8. X-ray diffraction spectroscopy (XRD)
X-ray powder diffraction analysis was performed using a Bruker D8
Advance X-ray powder diffractometer with a silicon drift detector on
powdered samples using Cu Ka 1.5418 Å radiation and Ni-ﬁlter with
2Ɵ from 18° to 60°.
2.9. Statistical analysis
Data are expressed as means ± standard deviations (SD) values
fromat least two experiments. The signiﬁcance levels (p-values) are cal-
culated using the t-test by MedCalc Software for multiple comparisons.
Differences in the variables are considered signiﬁcant at p b 0.05 and
speciﬁed in corresponding ﬁgures.
3. Results and discussion
3.1. Fabrication of CaCO3-mucin hybrids
Pure CaCO3 microcrystals (diameter of 5–6 μm) synthetized in this
study do not possess high surface charge (ζ-potential of 9 ± 2 mV)
that is in a good agreementwith previous reports [15,40]. Their capacity
for the DOX is rather low (average content of 0.11 mg g−1 CaCO3). Onecan assume that the loading capacity of the crystals for DOXor other rel-
evant drugsmay be enhanced if the crystals are also loadedwith a com-
ponent that can strongly interact with the drugs. This is further
investigated here using glycoprotein mucin as a matrix to host DOX
and/or other drugs. Being the major component of the mucus, mucin
seems to serve as an appropriate constituent element for mucosal
drug delivery system. In addition, a number of various interactions
(electrostatics, hydrophobic interactions, and hydrogen bonding) at-
tributed to mucin also makes this glycoprotein favorable candidate for
the formation of drug-binding polymer matrix. The structure of DOX
displays the only one changed group (primary amino group) that may
drive electrostatic attraction to sialic acid in mucin (Fig. 1) and hydro-
phobic anthracycline core tending to hydrophobic interaction with
cysteine-rich domains.
Hybrid CaCO3-mucin crystals have been prepared by co-synthesis.
Mucin has been added to solution of CaCl2 followed by addition of
Na2CO3 during intensive stirring that results in the growth of vaterite
crystals containing embedded mucin molecules (Fig. 2, I). DOX-
containing hybrids have been synthetized by simultaneous addition of
DOX and mucin during the synthesis as shown in the scheme.
It is known that the concentration ofmucin plays a key role in aggre-
gation of mucin molecules and gelation of mucin solution as a result of
the aggregation [56]. One can assume that the concentration of mucin
during the co-synthesismay affect the structure and properties of theﬁ-
nally formed crystals. First we have evaluated how much of mucin can
be loaded into the crystals as a function of initial mucin concentration
during the co-synthesis process. Fig. 3 shows the adsorption isotherm
for mucin loading.
The results presented in Fig. 3 have been ﬁtted by the classical equa-
tion for the Langmuir adsorption model (Eq. (3)). The linearization of
the adsorption isotherm in double reciprocal, i.e. 1/qe = f(1/Ce), allows
one to receive both qmax = 588 ± 35 mg g−1 and Ка = 0.50 mL mg−1
(R2 0.992). These thermodynamic parameters are 3.7 and 5 times higher
than those obtained for adsorption of mucin into pre-formed vaterite
crystals [40]. We assume that much higher loading of mucin via the
co-synthesis than that for the adsorption can be explained by the aggre-
gation of mucin molecules inside the pores of the crystals during the
crystal growth. Similar loading mechanism has been proposed for the
protein catalase that has been loaded into the crystals in enormous
amounts giving the concentration of the protein inside the crystals of
N200mgmL−1 [29].We assume thatmucin can be loaded at even larger
amounts only due to the formation of a mucin hydrogel inside the crys-
tal pores.
Interestingly, the free Gibbs energy change calculated for the loading
ofmucin via the co-synthesis (−31±3 kJmol−1) is slightly higher than
that obtained for themucin loading via adsorption onto performed crys-
tals (−35± 4 kJ mol−1) [40]. This can likely be caused by the presence
of intermolecular interactions betweenmucinmolecules for the loading
by the co-synthesis. These interactionsmay be less favorable than those
between crystals surface and mucin because of potential release of
water molecules in the case of mucin adsorption on the surface. Inter-
molecular mucin-mucin interactions result in formation of highly hy-
drated hydrogel. Nevertheless, rather low ΔG indicates a strong
afﬁnity of mucin to the crystals for the co-synthesis.
ζ-potential measurements have proven the presence of mucin on
the surface of the crystals. Hybrid crystals have the ζ-potential of -(8
± 2) mV, whereas bare crystals are positively charged having the ζ-
potential of +(9 ± 2) mV and mucin is negatively charged in aqueous
solution giving the ζ-potential of -(15 ± 2) mV. The inversion of the
ζ-potential sign of the surface for mucin-containing hybrids indicates
recharging of the crystal surface and an integration of mucin into the
crystals.
The morphology of mucin-containing crystals has been assessed
using SEM. Fig. 4 shows images of bare crystals (a, c) and those prepared
with mucin at highest glycoprotein concentration used, i.e. 6 mg mL−1
(Fig. 4b, d). The average diameter of the crystals has been increased in
Fig. 2. Schematic illustration of (I) the co-synthesis of CaCO3-mucin hybrid crystals containing DOX and (II) the release of DOX at physiological conditions via diffusion of mucin-DOX
complex out due to recrystallization of the CaCO3 crystals to calcite (IIa) and the complex diffusion out of the pores of the vaterite crystals (IIb).
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mucin, respectively). At the same time, the surface morphology of the
hybrids has been changed (Fig. 4c, d). The vaterite crystals are made
of small spherical nanocrystals, so called nanocrystallines [15]. SEM im-
ages indicate that the size of nanocrystallines for hybrids is signiﬁcantly
smaller than that for bare crystals. The analysis of the crystal surface
morphology has revealed average sizes of the nanocrystallines of 109
± 25 and 47 ± 7 nm for bare crystals and hybrids, respectively
(Fig. 4e, f). The direct assessment of the porosity of hybrid mucin-
containing crystals via Brunauer-Emmett-Teller surface area analysis is
limited due to relatively low thermal stability ofmucin that partially de-
composes already at 60 °C [57]. However, referring to themorphological
analysis of the vaterite crystals that directly correlates the outer surface
morphology with the internal structure of the crystals [15], the results
above allow one to conclude that the internal structure of the hybrids
is likely more developed, i.e. has smaller pores and a larger surface
area. Using the inverse relationship between nanocrystalline radii and
total surface area of spherical crystals derived in [15] and based on Ost-
wald ripening mechanism of crystal growth, it is possible to estimate
that hybrid crystals possess roughly 2.3 times larger area for hosting
molecules.
More porous structure of the hybrids provides excellent perspec-
tives to better retain the loaded mucin as well as other drugs to be co-
loaded via co-synthesis, for instance DOX and APR as discussed in the
following section.
Solid samples of CaCO3 and hybrid crystals have shown similar pat-
tern of FTIR spectra (Fig. 5) for which characteristic peaks of the carbon-
ate (broad peak at about 1300–1400 cm−1) and in particular vaterite
polymorph of CaCO3 (747, 876 cm−1 [58]) have been dominating. NoFig. 3. Adsorption isotherm formucin loading into vaterite CaCO3 crystals by co-synthesis.shifts of the bands indicating the recrystallization of vaterite to calcite
in the presence of mucin have been detected; the crystals are pure
vaterite polymorph. In hybrid crystals, no appearance of characteristic
bands of mucin has been detected that might be related to low signal
to noise ratio of characteristic amide bonds to CaCO3 background that
is below detection limit.
3.2. CaCO3-mucin-drug hybrids
In this part of the work the use of co-synthesis for the fabrication of
CaCO3-based drug delivery carriers for rather small drugs of different
nature is examined. For this, three well-known therapeutic drugs have
been chosen: DOX (small antibiotic of a molecular mass below 1 kDa)
and two protein-based drugs with different net charge, i.e. protease in-
hibitor aprotinin (APR) and a hormone insulin (INS). Physical-chemical
properties of the drugs are summarized in the Table 1 below. Two
protein-based drugs with different net charges have been chosen to as-
sess the contribution of electrostatic interactions for rather small drugs
of deﬁned dimensions and charges.
Isoelectric point of mucin is in the range of 3–4 and thus glycopro-
tein possesses a negative charge at the physiologically relevant pH 7.4.
This provides an opportunity to form interactionswith other substances
not only through hydrogen bonding and hydrophobic interactions but
also via rather strong columbic interactions (Fig. 1).
The loading of drugs into CaCO3-mucin-drug hybrids has been per-
formed in the presence of 30 mM TRIS buffer (pH 7.1) to ensure that
the ﬁnal pH during the co-synthesis is in the range 8.0–8.5. This pH is
considerably lower than that for the co-synthesis in water (pH of
about 10.3). Lower pH is beneﬁcial since it would providemilder condi-
tions for loading of protein-based drugs since the majority of labile
proteins are pH-sensitive and highly alkaline pH may be harmful for
them [62].
Fig. 6 shows the loading efﬁciency and the amount of released drug
for the co-synthesis in the absence (CaCO3-drug) and the presence of
mucin (CaCO3-mucin-drug). The efﬁciencies for loading of DOX and
APR are signiﬁcantly lower than that for INS (Fig. 6a) which is likely
caused by electrostatic attraction of negatively changed INS to positively
charged crystals. Inclusion ofmucinmatrix yields the negative charge to
hybrid crystals provoking slight reduction in INS entrapment efﬁciency.
On the contrary, both DOX and APR possess positive net charge in
the pH range of 8.0–8.5 and prone to electrostatic repulsion with posi-
tively charged CaCO3 crystals. The presence of mucin in the hybrid crys-
tals signiﬁcantly enhances the loading capacity for DOX and APR
(Fig. 6a) by 3–5 times (compared to that with no mucin).
The release of the encapsulated drugs (Fig. 6b) supports the hypoth-
esis above. The same amount of INS is released from mucin-containing
hybrids and mucin-free crystals proving that the presence of mucin
Fig. 4. SEM images of pure vaterite crystals (a,c) and those prepared with mucin via co-synthesis (b,d). Proﬁles (e) and (f) are taken along the white solid lines on the crystal surfaces, to
demonstrate a variation of a surface roughness in (c) and (d), respectively. Mucin concentration during the co-synthesis is 6 mg mL−1.
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amounts of DOX and APR released from mucin-containing crystals are
almost twice lower than those released from mucin-free crystals, this
difference is statistically signiﬁcant for APR andhas a high level of signif-
icance (p= 0.06) for DOX.
XRD pattern of hybrid CaCO3 crystals obtained in the presence of
mucin or mucin-DOX has been compared with vaterite synthetized
without any additives (Fig. 7). The powder XRD exhibits the character-
istic reﬂections of vaterite with dominant lattice planes of (004), (110),
(112), (114), (300) and (118) and less intensive (205), (008), (304) and
(224) calculated for the hexagonal cell with a = b = 7.169 Å and c =
16.981Å [63,64]. A negligible peak at 29.2° corresponding to rhombohe-
dral calcite structure also has been detected. No difference in relative
Bragg peak intensities (the same XRD pattern) for pure and hybrid crys-
tals points on the absence of morphological changes in the presence of
mucin and mucin-DOX that is in agreement with the results of FTIR
(Fig. 5). Small broadening of the peaks (an increase in FWHM of
11–17% as calculated for characteristic peaks of 224, 118 and 300) indi-
cate slight decrease in nanocrystallines size that collaborates with SEM
(Fig. 4). Signiﬁcant decrease in the intensity of vaterite observed in
the presence of mucin or mucin-DOX is due to the shielding effect of
amorphous mucin coating that is indicative for the inclusion of mucin
and mucin-DOX in non-crystalline state. Finally, characteristic peaks of
mucin (diffraction peaks at 31.3° and 45.2°) or DOX (multiple peaks
appearing within diffraction angle of 10–20°) have not been found
also indicating the entrapment of amorphous mucin and mucin-DOX
complex.In order to better understand the interaction ofmucin and the drugs,
analysis of themucin-drug complex has been done for DOX as described
in the following section.
3.3. Analysis of the complex mucin-DOX
The complexation between DOX and mucin has been probed by
ATR-FTIR spectroscopy. Characteristic bands of functional groups are
typically assessed focusing on the wavelength of the band as well as
on the shape and the width [55,65,66]. Overlapping of characteristic
bands limits proper analysis of the complexation between mucin and
APR as well as mucin and INS since all of these substances contain pep-
tide bonds with characteristic Amide I, II, and III bands. At the same
time, the overlapping of characteristic bands of mucin (Fig. 8) and
DOX (Fig. S1) is not signiﬁcant.
Interaction betweenDOX andmucin has been probed via two exper-
iments. In the ﬁrst experiment, the concentration of mucin was kept
constant (3 mg mL−1) and DOX concentration has been varied in the
range of 0.01–0.2 mg mL−1 (Fig. 9a). As a negative control for this, the
solutions of DOX of varied concentrations have been used.
Mucin contains many C-O-C bonds with the characteristic absorp-
tion band of 1060–1090 см−1 (Fig. 8) [66]. The increase of the concen-
tration of DOX at a ﬁxed concentration of mucin resulted in the
increase of the intensity of this band as shown in Fig. 9a. After the critical
concentration of DOX of N0.05 mgmL−1, the value of the peak intensity
has reached a plateau. It is of note that the DOX also contains a sugar
moiety as mucin but its contribution to the measured spectra has been
Fig. 5. Normalized solid-phase FTIR absorbance spectra of (a) mucin, (b) CaCO3, (c) CaCO3-mucin and (d) CaCO3-mucin-DOX hybrids. Mucin and DOX have been loaded in terms of co-
synthesis (initial concentrations during loading were 4 mg mL−1 for mucin and 0.1 mg mL−1 for DOX).
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ated with a change of the microenvironment of pyranose cycles in
mucin as has been reported in the following works [55,67]. One can as-
sume that these changes are mediated by noncovalent interactions be-
tween aromatic rings of DOX and sugar moieties [68]. However, at the
point of reaching the plateau, the molar ratio between the DOX and py-
ranose cycles of mucin molecules is roughly 1:100. In other words,
about only one DOX molecule per 100 sugar moieties of mucin mole-
cules induces signiﬁcant changes in the local microenvironment of
mucin. Since this ratio of 1:100 is rather low, it can be assumed that
carbohydrate-aromatic interactions are inﬂuenced not via direct
monosaccharide-anthracycline binding but via electrostatic interaction
between carboxylic groups in sialic acid residues of mucin and amino
groups of DOX. In the structure of DOX, the amino group is covalently
bound to the pyranose cycle, so the interaction of the amino group
with the carboxylic group would result in changes in themicroenviron-
ment of the pyranose cycle of DOX and consequently affect
carbohydrate–aromatic interactions. At the point of reaching the pla-
teau in Fig. 9a (DOX concentration of 0.05mgmL−1), themolar ratio be-
tween DOX and sialic acid residues of mucin molecules (content of
around 2.3%) is roughly 1:2.Table 1
Physical-chemical characteristics of the drugs used in this study for loading into CaCO3-
mucin-drug hybrids via co-synthesis. Dh - Hydrodynamic diameter.
Drug Bio-function MW, Da pI Dh, nm Ref.
DOX Anticancer drug 544 8.6 0.5 [59]
APR Protein-based protease inhibitor 6500 10.5 2.9 [60]
INS Hormone 5800 5.3 2,7 (monomer)
5,1 (hexamer)
[61]Electrostatic attraction between NH2 and carboxylic group of si-
alic acid has further been corroborated by the second ATR-FTIR ex-
periment. Deprotonation of the carboxylic group and formation of
the COO– ion that has a characteristic band in 1330–1390 cm−1
[69] has been detected (Fig. 9b). It is of note that the characteristic
band of the CH2 group may be found nearby the band for the COO–
group, however, these peaks are easy to distinguish by their inten-
sities and half-widths. For instance, the peaks of CH2 (deform.) are
usually rather wide and have low intensities (for the polymers that
are not enriched with CH2 groups) while the peaks of the carbox-
ylic group are typically narrow. Moreover, the deformation oscilla-
tions usually have less intensity of peaks and are typically less used
in the analysis.
The concentration of mucin has been varied in the range of
2–4 mg mL−1, while DOX concentration was kept constant for
each measurement at 0.1 mg mL−1 (Fig. S2). The negative control
was chosen as for the ﬁrst experiment above, i.e. the DOX solution
of a corresponding concentration. Fig. 9b demonstrates results of
this experiment where it is clear that the peak intensity reaches a
plateau at the concentration of mucin N 3 mg mL−1. Notably, the
plateau in Fig. 9b corresponds to the molar ratio between DOX
and sialic acid residues of mucin molecules of 1:1. This reveals
the pivotal role of electrostatic interaction in mucin-DOX binding,
yet hydrophobic interactions also might have some impact on
mucin-DOX binding as it has been previously reported in [40].
This can be associated with the binding to cysteine-rich domain
of mucin (Fig. 1), although more detailed study should be per-
formed to justify this in future.
Further we considered an effect of mucin concentration on the
loading/release of DOX into/from the hybrids of CaCO3-mucin-
DOX.
Fig. 6.Average drug content per theCaCO3-mucin-drug hybrid crystal (a) and the amount of drug released from the hybrids (b). Hybrids are prepared by co-synthesis at the concentrations
ofmucin and drugs of 1mgmL−1 (only for DOX the concentration is 0.1mgmL−1). The release of the drugs from the hybrids is carryout out in 50mMTRIS buffer, pH 7.4, 24 h incubation.
p-Values are obtained by comparison of groups indicated: * p b 0.02; # p= 0.06.
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First, the inﬂuence of mucin concentration at co-synthesis on the
loading of DOX into the hybrids has been investigated (Fig. 10). It has
been observed that the higher is the concentration of the used mucin,
the higher is the amount of the loaded DOX. Notably, the amount of
the DOX loaded into the crystals is at least one order of magnitude
higher in the presence of mucin compared to the bare crystal. Encapsu-
lation efﬁciencies (η) reached via entrapment to CaCO3-mucin-DOX hy-
brid crystals (Fig. 10a) are comparable with those for other DOX
delivery systems, e.g. polymeric micelles (η of ca 30%) [70] or hydrogels
(η 20–40%) [71]. Suspension of the crystals loaded with DOX become
coloured as can be clearly observed visually (Fig. S3). This was the
case after double washing of the crystals indicating a strong binding of
DOX to the hybrid crystals.
At the next step, release mechanism and kinetics have been investi-
gated. Obviously, mucosa of different organs has different environment
that also might differ in healthy and pathological tissues that might se-
riously affect the release proﬁles. In this study, we have focused on DOX
release at pH 7.4 that is relevant to some important clinical cases
(Table S1).
First, an effect of the initial mucin concentration on the release of
DOX from the hybrids at physiologically relevant conditions has been
analyzed. Simultaneous assessment of DOX and mucin release has
been performed in order to conclude whether the mucin and DOXFig. 7. XRD pattern of CaCO3, CaCO3-mucin and CaCO3-mucin-DOX hybrids. Mucin and DOX
4 mg mL−1 for mucin and 0.1 mg mL−1 for DOX).releases are dependent processes. Fig. 11 presents both the relative
amount of mucin and DOX released after incubation of the hybrids in
TRIS (37 °C) for 24 h. This analysis has been accompanied by the inves-
tigation of the morphology of the crystals. The content of spherical
vaterite crystals and more thermodynamically stable polymorph of
cubic calcite crystals has been identiﬁed (Fig. 11, upper panel). Higher
concentration of mucin used for the fabrication of hybrid crystals re-
sulted in deceleration of the release for both mucin and DOX; this has
been accompanied by an increase of the content of vaterite over calcite
polymorph as recorded at 24 h of incubation. The crystals prepared
without mucin have been completely recrystallized to calcite and re-
leased almost all DOX after 24 h. In contrast, the hybrid crystals with
the highest content of mucin used (4 mg mL−1 concentration during
the co-synthesis) have not been recrystallized at all and kept their
vaterite structure, releasing only about a third of the loaded mucin
and DOX (Fig. 11). This indicates a strong inﬂuence of mucin on both
the recrystallization of vaterite to calcite and on the rate of DOX release
rate. Mucin inhibits recrystallization process thatmay be caused by hin-
dering the ion transport (Ca2+ and CO32−) from the crystal surface due
to binding to mucin (recrystallization is the solution-mediated process
[72]).
Another interesting ﬁnding is that at the tested conditions the
amounts of released DOX and mucin are rather similar. This indicates
that DOX is released as a complex with mucin. Taking into account the
results of ATR-FTIR study described above, it is reasonable to assumehave been loaded in terms of co-synthesis (initial concentrations during loading were
Fig. 8. Normalized FTIR spectrum of mucin (3 mg mL−1, 30 mM TRIS buffer pH 7.1, 22 °C).
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leased as a complex as well. Moreover, the release rate is dependent
on the polymorph state of the crystals. The substantial release of the en-
capsulated components takes place as soon as the vaterite polymorph is
transferred to thermodynamically more stable calcite. Due to non-
porous structure of the calcite, the content of the crystals (both mucin
and DOX) will release out.
Consequently, the kinetics of DOX release from the hybrids has been
investigated. Fig. 11 shows the relative amount of the released DOX as a
function of time for the release experiment in 50 mM TRIS buffer,
pH 7.4. The release kinetics shows a burst within 1 h followed by a
very slow sustained release up to approximately 6 h. At this time
point, about 90% of DOX has been released from bare crystals fabricated
without mucin while only ca. 30% of DOX has been liberated from hy-
brid crystals fabricated using mucin concentration of 1–4 mg mL−1.
The ratio of the released drug from the crystals prepared with/without
mucin has been signiﬁcantly changed after 24 h demonstrating an in-
crease of the released amount of DOX from the hybrid crystals. Herein,
higher mucin concentration suppresses the release rate. Longer-term
release of DOX (after 24 h) has not been considered in this study and
should be described in future works.Fig. 9. The dependence of the intensity of the bands 1037 cm−1 corresponding to C-O-C os
concentration of DOX and the constant concentration of mucin (3 mg mL−1) or (b) - varied
TRIS buffer solution, pH 7.1, 22 °C.These results, considered togetherwith the results in Fig. 11, obviously
demonstrate that the recrystallization of vaterite to calcite plays a crucial
role in the release kinetics. Non-porous calcite crystals cannot provide
enough surface area to host DOX and mucin, the recrystallization results
in a substantial release of both components of the hybrids. Of note,
mucin and DOX are released dependently (Fig. 11) and one can reason-
ably assume that the release of mucin is primary important to control
the release rate of DOX since DOX is bound to mucin as shown in the
ATR-FTIR study above. The strong effect of the recrystallization on the re-
leased amount of the encapsulated cargo has been shown previously [26]
and the results shown in the Fig. 12 proves that the change in the porosity
of vaterite and calcite polymorphs can effectively be used to control the
release of substances pre-encapsulated into the vaterite CaCO3 crystals.
Our preliminary in vitro experiments have demonstrated the efﬁ-
cient uptake of CaCO3 crystals byHepG2 and SK-Hep-1 human liver can-
cer cells. Moreover, ﬁlling of CaCO3 crystals with carboxymethyl-
dextrans and formation of model negatively charged macromolecular
matrix inside the crystals improved cellular uptake (data are not
shown). This is promising indicator for our upcoming in vitro study,
where the questions of the mechanisms of cellular uptake and intracel-
lular drug release are addressed.cillations and 1339 cm−1 corresponding to COO– oscillations of mucin on: (a) - varied
concentration of mucin and the constant concentration of DOX (0.1 mg mL−1). 30 mM
Fig. 10. The average entrapment efﬁciency (a) and DOX content (b) in CaCO3-mucin-DOX hybrid crystal as a function of mucin concentration (C0) during co-synthesis.
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This study demonstrates that co-synthesis of the anticancer drug
DOX and mucin can signiﬁcantly improve DOX loading (by at least ten
times providing concentration of 1.33mgmL−1 DOX inside the crystals)
and offer a control over the drug release rate from the crystals. Here-
with, the content of mucin in the hybrid crystals can reach extremely
high value (adsorption capacity of 588 ± 35 mg g−1) that exceeds the
maximal values possible to be obtained in the solution indicating the
formation of a gel in the crystal pores.Mucin binding to the crystals dur-
ing co-synthesis is strong giving Ка of 0.50 mL mg−1 and the free GibbsFig. 11. The inﬂuence of the mucin concentration set during the co-synthesis on the relative a
presence of vaterite (V) or/and calcite (C) polymorph. The release is assessed after 24 h of in
calcite and vaterite polymorphs, respectively. Pre-loaded amount of DOX (red) or mucin (whit
(0 mg mL−1 mucin): *p= 0.05; **p= 0.03. (For interpretation of the references to colour in tenergy change of −31 ± 3 kJ mol−1. DOX is bound preferentially by
electrostatic attraction of its amino group to carboxylic groups of
mucin as has been proven employing ATR-FTIR spectroscopy. The pres-
ence of mucin results in the reduction of pore sizes of the vaterite crys-
tals that taken togetherwith the crystals recrystallization to non-porous
calcite polymorph, suppresses DOX release at physiologically relevant
conditions. The DOX release is bimodal starting with a burst of ca 1 h,
followed by a sustained release within the time scale of tens of hours.
This study opens a new avenue for encapsulation and controlled release
of small hydrophilic drugs towards applications in mucosal delivery
since mucin is a main component of the mucosa and is shown here tomount of release DOX and mucin (in % of encapsulated into hybrids) and the dominating
cubation in 50 mM TRIS buffer, pH 7.4. C + V and V + C demonstrate dominating of the
e) has been taken as 100%. p-values were obtained by comparison of groups with control
his ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 12. Kinetics of release of DOX from CaCO3-mucin-DOX hybrids in 50 mM TRIS buffer,
pH 7.4 for different mucin concentrations used during co-synthesis of the hybrid crystals.
Pre-loaded amount of DOX has been taken as 100%.
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that the concentration ofmucin used during the co-synthesis can signif-
icantly affect the DOX release performance and thus can be used for pre-
programming and control over the drug release. The pivotal role of elec-
trostatic interaction betweenmucin and thedrugs is supported byprob-
ing the binding of DOX (pKa 8.6) and two small protein-based drugs, i.e.
APR (pI 10.5) and INS (pI 5.3). DOX is released as a complex withmucin
due to a strong interaction driven by Coulomb attractive forces. More-
over, the release strongly depends on the polymorph state of the crys-
tals: the increase of the mucin content in the hybrids reduces the DOX
release rate via stabilization of the porous vaterite crystals against re-
crystallization to non-porous calcite. In addition, the presence of
mucin reduces the crystal pore size that makes crystals more capable
for the DOX loading and may be used to adjust the DOX release rate.
This study of the growth of vaterite microcrystals in the presence of
mucin might contribute to a better understanding of the processes of
biomineralization of calcium carbonate, that typically plays a pivotal
role in crystallization during the pathological formation of calculus in
organs internally covered with mucous membrane. Vaterite crystals
which are crystallized in the presence of highmucin concentrations cor-
responding to those in mucus, better retain cationic bioactives and
posess substantial stability under physiological conditions that makes
them promising candidates for mucosal drug delivery. Filling of porous
vaterite crystals with gel-like matrix of mucin might become a simple
and powerful approach for the formulation of CaCO3-based drug deliv-
ery systems.
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